Related Topics

LinkedIn
Vimeo
Facebook

FSHD

FSHD video from Genea Biocells on Vimeo.

Nuclei in FSHD-affected stem cell-derived myotubes turn green when DUX4 is expressed followed by death of the cell

Facioscapulohumeral muscular dystrophy (FSHD)

FSHD represents a major unmet clinical need arising from the progressive weakness and atrophy of skeletal muscles. To date, no treatment is available for FSHD. The dearth of adequate experimental
models has severely hampered our understanding of the disease and the development of new therapies. Genea Biocells’ technology platform using human pluripotent stem cells (hPSC) represent a renewable, inexhaustible and readily available source of skeletal muscle cells and provides an alternative to invasive and variable patient biopsies. We developed the world’s first human stem cell model of FSHD which shows cellular hallmarks of the disease and which we used successfully to develop a range of primary and secondary drug screening assays. Our earlier research was supported by FSHD Global and Friends of FSH Research.

Therapeutic Approach

FSHD represents a major unmet clinical need arising from the progressive weakness and atrophy of skeletal muscles. To date, no treatment is available for FSHD. The dearth of adequate experimental
models has severely hampered our understanding of the disease and the development of new therapies. Genea Biocells’ technology platform using human pluripotent stem cells (hPSC) represent a renewable, inexhaustible and readily available source of skeletal muscle cells and provides an alternative to invasive and variable patient biopsies. We developed the world’s first human stem cell model of FSHD which shows cellular hallmarks of the disease and which we used successfully to develop a range of primary and secondary drug screening assays. Our earlier research was supported by FSHD Global and Friends of FSH Research.

About FSHD

Facioscapulohumeral Dystrophy (FSHD) is an inheritable muscle disease affecting about 1:8,000 people. There is no cure or treatment strategy for patients with FSHD. This debilitating disease slowly consumes skeletal muscle, robbing people of the active, healthy, and independent years of their lives.

FSHD is a genetic disease resulting in progressive muscle weakness

Onset is typically in young adults

Affects ~1:8,000 people

FSHD is caused by aberrant upregulation of DUX4 – a protein toxic to muscle

For more information on FSHD visit:

MDA

Friends of FSH Research

FSHD Global